PDCD1 and gastric cancer: To further determine whether forced sLGMN expression is associated with the resistance of gastric cancer to anti-PD-1 immunotherapy, ELISA was used to detect the expression levels of serum sLGMN in 30 GC patients treated with PD-1 monoclonal antibody therapy.